Andersons pediatric cardiology 2352
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (78.53 KB, 3 trang )
aorticisthmusin,87,87f
arterialductin,87
inhealthanddisease,90–96,90f
ovalforamenin,87
placentain,85–86,86f
venousductin,86–87,86f
embryoniccirculationand,83,84f
fetalvolumebloodflowmeasurement,99f–100f,100–101
globalcardiacfunctionof,97–98
myocardialstrainandstrainrate,97–98,99f
TEIindex,97,97f
heartfailureand,85
longaxisfunctionof,96–97
Dopplertissueimagingand,97
M-modemeasuresofatrioventricularringdisplacementand,96–97
maturationalchangesin,87–90
postmortemstudies,88–90,89f–90f
invivostudies,87–88,88f
β-myosinand,85
rate,variabilityof,103–104,104f–105f
troponinand,85
vascularphysiology,101–102,101f
vascularprogramming,104–106
followingfetalcoarctation,106,106f
insettingofrestrictedgrowth,104–106
intwin-twintransfusionsyndrome,106
ventriculovascularcoupling,102–104
Fetalheartdisease,antibody-mediated,142–144
Fetalheart-placentalaxis,159
Fetalhemodynamics
braingrowthanddevelopmentand,121–122
lungdevelopmentand,122,122f–123f
Fetalhydrops,directfetaltreatmentand,140
Fetalhyperthyroidism,142
Fetalinterests,ethicalissuesand,1468
Fetalinterventions,ofethicalissues,1467–1469
Fetalpressure-volumeloops,102–103,103f
Fetalprogramming,157
Fetalsystemicpressures,102,102f–103f
Fetaltelemedicine,1555
Fetoplacentalcirculation,85–87
aorticisthmusin,87,87f
arterialductin,87
ovalforamenin,87
placentain,85–86,86f
venousductin,86–87,86f
Fetus
cardiacdevelopmentin,87–90
listingfortransplantation,1226–1227
percutaneousinterventionin,149–156
forestablishedhypoplasticleftheartsyndromewithintactorhighlyrestrictiveatrialseptum,154–155
futuredirectionsfor,155–156
forpulmonaryatresiawithintactventricularseptumandevolvinghypoplasticrightheartsyndrome,153–154
forseveremidgestationaorticstenosiswithevolvingleftheartsyndrome,149–153
pharmacologicinterventionin,137–147
antiarrhythmicfetaltreatmentas,137–142
antiinflammatoryfetaltreatmentas,142–144
heartfailuretreatmentas,144
supplementaryoxygenation,144–147
vascularphysiologyof,assessmentof,101–102,101f
Fever,inrheumaticfever,1011
Fibrillin,1355–1356
Fibrillin-1gene,arterialdysfunctionand,1373
Fibrinsealants,inhemostasis,1289
Fibroblasts,inmyocardialdevelopment,62–64,63f–64f
Fibromas,cardiac,971–972,972f
Fibrousskeleton,ofheart,28,28f
Filters,incardiopulmonarybypass,227
First-degreeAVblock,337
First-degreerelatives,screening,aftersuddencardiacdeath,inyoung,1538–
1540
ethicalconsiderationsandfuturedirectionsfor,1540
genotype,1539–1540,1540t
phenotype,1539,1540f
Fistulas
arterio-venous,coronary
clinicalfeaturesof,937–938
investigationsin,938–940,939f–940f
long-termoutcomesof,941–944,942f–943f
managementof,940–941,941f
morphologyof,936–937,937f–938f
ofcoronaryarteries,99–100
Flecainide,1437
foratrialtachyarrhythmias,138–140,139t
Flow,ratesof,incardiopulmonarybypass,227–228
Flucloxacillin
forbloodculture-negativeendocarditis,1054t
forinfectiveendocarditis,1053t
Fluiddynamics,computational,foruniventricularheart,1350
Fluidmanagement,forhemodynamicallysignificantarterialduct,198
Fluidrequirements,1498t
Fluoroscopycameraangles,243t
Focalatrialtachycardia,357
Fontancirculation
congenitallycorrectedtranspositionand,714
nutritionand,1503
inpregnancy,1446
foruniventricularheart
arrhythmiain,1324–1329,1324f
atrialfibrillation,1328
atrialtachyarrhythmias,1327–1328
